RATIONALE: Sepsis therapeutics have a poor history of success in clinical trials, due in part to the heterogeneity of enrolled patients. Pharmacometabolomics could differentiate drug response phenotypes and permit a precision medicine approach to sepsis. OBJECTIVES: To use existing serum samples from the phase 1 clinical trial of l-carnitine treatment for severe sepsis to metabolically phenotype l-carnitine responders and nonresponders. METHODS: Serum samples collected before (T0) and after completion of the infusion (T24, T48) from patients randomized to either l-carnitine (12 g) or placebo for the treatment of vasopressor-dependent septic shock were assayed by untargeted (1)H-nuclear magnetic resonance metabolomics. The normalized, quantified metabolite data sets of l-carnitine- and placebo-treated patients at each time point were compared by analysis of variance with post-hoc testing for multiple comparisons. Pathway analysis was performed to statistically rank metabolic networks. MEASUREMENTS AND MAIN RESULTS: Thirty-eight metabolites were identified in all samples. Concentrations of 3-hydroxybutyrate, acetoacetate, and 3-hydroxyisovalerate were different at T0 and over time in l-carnitine-treated survivors versus nonsurvivors. Pathway analysis of pretreatment metabolites revealed that synthesis and degradation of ketone bodies had the greatest impact in differentiating l-carnitine treatment response. Analysis of all patients based on pretreatment 3-hydroxybutyrate concentration yielded distinct phenotypes. Using the T0 median 3-hydroxybutyrate level (153 μM), patients were categorized as either high or low ketone. l-Carnitine-treated low-ketone patients had greater use of carnitine as evidenced by lower post-treatment l-carnitine levels. The l-carnitine responders also had faster resolution of vasopressor requirement and a trend toward a greater improvement in mortality at 1 year (P = 0.038) compared with patients with higher 3-hydroxybutyrate. CONCLUSIONS: The results of this preliminary study, which were not readily apparent from the parent clinical trial, show a unique metabolite profile of l-carnitine responders and introduce pharmacometabolomics as a viable strategy for informing l-carnitine responsiveness. The approach taken in this study represents a concrete example for the application of precision medicine to sepsis therapeutics that warrants further study.
RCT Entities:
RATIONALE: Sepsis therapeutics have a poor history of success in clinical trials, due in part to the heterogeneity of enrolled patients. Pharmacometabolomics could differentiate drug response phenotypes and permit a precision medicine approach to sepsis. OBJECTIVES: To use existing serum samples from the phase 1 clinical trial of l-carnitine treatment for severe sepsis to metabolically phenotype l-carnitine responders and nonresponders. METHODS: Serum samples collected before (T0) and after completion of the infusion (T24, T48) from patients randomized to either l-carnitine (12 g) or placebo for the treatment of vasopressor-dependent septic shock were assayed by untargeted (1)H-nuclear magnetic resonance metabolomics. The normalized, quantified metabolite data sets of l-carnitine- and placebo-treated patients at each time point were compared by analysis of variance with post-hoc testing for multiple comparisons. Pathway analysis was performed to statistically rank metabolic networks. MEASUREMENTS AND MAIN RESULTS: Thirty-eight metabolites were identified in all samples. Concentrations of 3-hydroxybutyrate, acetoacetate, and 3-hydroxyisovalerate were different at T0 and over time in l-carnitine-treated survivors versus nonsurvivors. Pathway analysis of pretreatment metabolites revealed that synthesis and degradation of ketone bodies had the greatest impact in differentiating l-carnitine treatment response. Analysis of all patients based on pretreatment 3-hydroxybutyrate concentration yielded distinct phenotypes. Using the T0 median 3-hydroxybutyrate level (153 μM), patients were categorized as either high or low ketone. l-Carnitine-treated low-ketonepatients had greater use of carnitine as evidenced by lower post-treatment l-carnitine levels. The l-carnitine responders also had faster resolution of vasopressor requirement and a trend toward a greater improvement in mortality at 1 year (P = 0.038) compared with patients with higher 3-hydroxybutyrate. CONCLUSIONS: The results of this preliminary study, which were not readily apparent from the parent clinical trial, show a unique metabolite profile of l-carnitine responders and introduce pharmacometabolomics as a viable strategy for informing l-carnitine responsiveness. The approach taken in this study represents a concrete example for the application of precision medicine to sepsis therapeutics that warrants further study.
Authors: T Andrew Clayton; David Baker; John C Lindon; Jeremy R Everett; Jeremy K Nicholson Journal: Proc Natl Acad Sci U S A Date: 2009-08-10 Impact factor: 11.205
Authors: Michael A Puskarich; Jeffrey A Kline; Virginia Krabill; Heather Claremont; Alan E Jones Journal: JPEN J Parenter Enteral Nutr Date: 2013-07-12 Impact factor: 4.016
Authors: Christopher W Seymour; Sachin Yende; Melanie J Scott; John Pribis; Robert P Mohney; Lauren N Bell; Yi-Fan Chen; Brian S Zuckerbraun; William L Bigbee; Donald M Yealy; Lisa Weissfeld; John A Kellum; Derek C Angus Journal: Intensive Care Med Date: 2013-05-15 Impact factor: 17.440
Authors: Nikolaos Psychogios; David D Hau; Jun Peng; An Chi Guo; Rupasri Mandal; Souhaila Bouatra; Igor Sinelnikov; Ramanarayan Krishnamurthy; Roman Eisner; Bijaya Gautam; Nelson Young; Jianguo Xia; Craig Knox; Edison Dong; Paul Huang; Zsuzsanna Hollander; Theresa L Pedersen; Steven R Smith; Fiona Bamforth; Russ Greiner; Bruce McManus; John W Newman; Theodore Goodfriend; David S Wishart Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240
Authors: Kathleen A Stringer; John G Younger; Cora McHugh; Larisa Yeomans; Michael A Finkel; Michael A Puskarich; Alan E Jones; Julie Trexel; Alla Karnovsky Journal: Shock Date: 2015-09 Impact factor: 3.454
Authors: Charles R Evans; Alla Karnovsky; Michael A Puskarich; George Michailidis; Alan E Jones; Kathleen A Stringer Journal: J Proteome Res Date: 2019-04-01 Impact factor: 4.466
Authors: Brandon J Sonn; Jessica L Saben; Glenn McWilliams; Shelby K Shelton; Hania K Flaten; Angelo D'Alessandro; Andrew A Monte Journal: Metabolomics Date: 2019-10-03 Impact factor: 4.290
Authors: Alexander T Limkakeng; Andrew A Monte; Christopher Kabrhel; Michael Puskarich; Laura Heitsch; Ephraim L Tsalik; Nathan I Shapiro Journal: Acad Emerg Med Date: 2016-10-03 Impact factor: 3.451